Back to discover
Disease
Polycystic Kidney Diseases
Late-stage therapeutic developmentEmerging research
1
Publications
4
Clinical trials
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Immune checkpoint activity regulates polycystic kidney disease progression.
Research2023-06-22JCI insight
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
No activity recorded in this window. Try a wider timeframe.
Clinical trials
The current development programme across all trial phases.
Clinical programme
4
0
1
2
Late-stage studies
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Recent publications
Major themes2
- Polycystic Kidney Diseases1
- Polycystic Kidney, Autosomal Dominant1
Leading journals1
- JCI insight1
Leading researchers8
- Bauer CD1
- Berger MD1
- Chonchol MB1
- Clambey ET1
- Furgeson SB1
- Gitomer BY1
- Hopp K1
- Kleczko EK1
Affiliations (unnormalised)2
- University of Colorado Anschutz Medical Campus1
- University of Oklahoma Health Sciences Center1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.